Evidence map›Paper›PMID 25628092›Full record

ArticleBritish journal of cancer2015

Cell migration in paediatric glioma; characterisation and potential therapeutic targeting.

J V Cockle, S Picton, J Levesley, E Ilett, A M Carcaboso, S Short, L P Steel, A Melcher, S E Lawler, A Brüning-Richardson

Open access · hybridAbstract read
In one paragraph

Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Frontiers in oncology · 2020
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Indirubin and Indirubin Derivatives for Counteracting Proliferative Diseases.Evidence-based complementary and alternative medicine : eCAM · 2015
    Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

J V Cockle1] Leeds Institute of Cancer Studies and Pathology, University of Leeds, Wellcome Trust Brenner Building, St James's University Hospital, Leeds, LS9 7TF, UK [2] Yorkshire Regional Centre for Paediatric Oncology and Haematology, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK.
S PictonYorkshire Regional Centre for Paediatric Oncology and Haematology, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK.
J LevesleyLeeds Institute of Cancer Studies and Pathology, University of Leeds, Wellcome Trust Brenner Building, St James's University Hospital, Leeds, LS9 7TF, UK.
E IlettLeeds Institute of Cancer Studies and Pathology, University of Leeds, Wellcome Trust Brenner Building, St James's University Hospital, Leeds, LS9 7TF, UK.
A M CarcabosoPreclinical Therapeutics and Drug Delivery Research Program, Department of Oncology, Hospital Sant Joan de Déu Barcelona, Preclinical Therapeutics and Drug Delivery Research Program Santa Rosa, 39-57, 4th floor 08950 Esplugues de Llobregat, Barcelona, Spain.
S ShortLeeds Institute of Cancer Studies and Pathology, University of Leeds, Wellcome Trust Brenner Building, St James's University Hospital, Leeds, LS9 7TF, UK.
L P SteelLeeds Institute of Cancer Studies and Pathology, University of Leeds, Wellcome Trust Brenner Building, St James's University Hospital, Leeds, LS9 7TF, UK.
A MelcherLeeds Institute of Cancer Studies and Pathology, University of Leeds, Wellcome Trust Brenner Building, St James's University Hospital, Leeds, LS9 7TF, UK.
S E LawlerDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, 4 Blackfan Circle, HIM 930A, Boston, MA, 02115, USA.
A Brüning-RichardsonLeeds Institute of Cancer Studies and Pathology, University of Leeds, Wellcome Trust Brenner Building, St James's University Hospital, Leeds, LS9 7TF, UK.
St James's University Hospital · GBUniversity of Leeds · GBBrigham and Women's Hospital · USHospital Sant Joan de Déu Barcelona · ESLeeds General Infirmary · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPaediatric high grade glioma (pHGG) and diffuse intrinsic pontine glioma (DIPG) are highly aggressive brain tumours. Their invasive phenotype contributes to their limited therapeutic response, and novel treatments that block brain tumour invasion are needed.

methodsHere, we examine the migratory characteristics and treatment effect of small molecule glycogen synthase kinase-3 inhibitors, lithium chloride (LiCl) and the indirubin derivative 6-bromoindirubin-oxime (BIO), previously shown to inhibit the migration of adult glioma cells, on two pHGG cell lines (SF188 and KNS42) and one patient-derived DIPG line (HSJD-DIPG-007) using 2D (transwell membrane, immunofluorescence, live cell imaging) and 3D (migration on nanofibre plates and spheroid invasion in collagen) assays.

resultsAll lines were migratory, but there were differences in morphology and migration rates. Both LiCl and BIO reduced migration and instigated cytoskeletal rearrangement of stress fibres and focal adhesions when viewed by immunofluorescence. In the presence of drugs, loss of polarity and differences in cellular movement were observed by live cell imaging.

conclusionsOurs is the first study to demonstrate that it is possible to pharmacologically target migration of paediatric glioma in vitro using LiCl and BIO, and we conclude that these agents and their derivatives warrant further preclinical investigation as potential anti-migratory therapeutics for these devastating tumours.

Indexed as

Cell MovementMolecular Targeted TherapyBrain NeoplasmsCell Line, TumorChildDose-Response Relationship, DrugDrug Evaluation, PreclinicalGliomaGlycogen Synthase Kinase 3HumansIndolesLithium ChlorideNeoplasm InvasivenessOximesProtein Kinase InhibitorsSpheroids, Cellular6-bromoindirubin-3'-oximeGlycogen Synthase Kinase 3IndolesLithium ChlorideOximesProtein Kinase Inhibitors

Identifiers

PMID25628092
PMCPMC4333505
OpenAlexW1976691094

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.